Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 23, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 24, 2026 — +18% at the close.
Predicted vs. what happened
What happened
Reached its target in 59 days.
The thesis — published February 23, 2026
Arrowhead looks like a short-term rebound idea after a big drop. A Feb 11 note said there are over 100 early prescriptions for REDEMPLO, which could steady investor mood and shift attention to how the company executes sales. But a lower price target shows some analysts remain cautious. Trade with a small position and tight rules because the stock can move quickly.
Primary drivers
- Early REDEMPLO prescriptions support its sales story
- Drug pipeline could cause bigger moves if news is positive
- Biotech sentiment shifts fast and can lift the stock
- Analyst caution means wait for confirmation and use stops
How it played out
ARWR: target reached in 59 days
Lyra published ARWR on 2026-02-23 at $63.50 as a short-term rebound idea with 20% expected growth. The thesis pointed to early REDEMPLO prescriptions, possible pipeline news, fast shifts in biotech sentiment, and analyst caution that called for confirmation.
Inside the window from 2026-02-23 to 2026-05-24, the stock reached the $76.20 target in 59 days. It later peaked at $82 on 2026-05-14, a 29.1% gain. It ended at $74.95. The thesis played out. The target was reached, and the close stayed above the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.